Khosla Ventures is a Menlo Park-based multi-stage venture capital firm that invests across seed through growth in technology and life sciences. It is one of the most established firms in frontier innovation and has the scale to support companies across multiple financing stages. Within that broader platform, it has developed a dedicated neurotech practice, giving it stronger sector specificity than many generalist firms.

Its neurotech strategy spans brain-computer interfaces, neuromodulation, and brain stimulation for neurological and psychiatric disorders. The portfolio includes companies such as Synchron, Kernel, Flow Neuroscience, and Paradromics, reflecting coverage across endovascular BCI, neuroimaging, depression-focused stimulation, and high-bandwidth neural interfaces. This makes Khosla one of the clearest examples of a large mainstream venture firm with a genuine, named neurotech investment focus.

Khosla Ventures invests globally, though its activity is centered primarily in the United States. For neurotech founders, it is especially relevant where companies combine bold technical ambition with platform-scale commercial potential. Its combination of sector focus, fund scale, and multi-stage support makes it one of the most important institutional investors in the neurotechnology landscape.